Browse FANCM

Summary
SymbolFANCM
NameFanconi anemia, complementation group M
Aliases FAAP250; KIAA1596; ATP-dependent RNA helicase FANCM; fanconi anemia-associated polypeptide of 250 kDa; prote ......
Chromosomal Location14q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF02732 ERCC4 domain
PF16783 FANCM to MHF binding domain
PF00271 Helicase conserved C-terminal domain
PF04851 Type III restriction enzyme
Function

DNA-dependent ATPase component of the Fanconi anemia (FA) core complex (PubMed:16116422). Required for the normal activation of the FA pathway, leading to monoubiquitination of the FANCI-FANCD2 complex in response to DNA damage, cellular resistance to DNA cross-linking drugs, and prevention of chromosomal breakage (PubMed:16116422, PubMed:19423727, PubMed:20347428, PubMed:20347429). In complex with CENPS and CENPX, binds double-stranded DNA (dsDNA), fork-structured DNA (fsDNA) and Holliday junction substrates (PubMed:20347428, PubMed:20347429). Its ATP-dependent DNA branch migration activity can process branched DNA structures such as a movable replication fork. This activity is strongly stimulated in the presence of CENPS and CENPX (PubMed:20347429). In complex with FAAP24, efficiently binds to single-strand DNA (ssDNA), splayed-arm DNA, and 3'-flap substrates (PubMed:17289582). In vitro, on its own, strongly binds ssDNA oligomers and weakly fsDNA, but does not bind to dsDNA (PubMed:16116434).

> Gene Ontology
 
Biological Process GO:0000712 resolution of meiotic recombination intermediates
GO:0006260 DNA replication
GO:0006261 DNA-dependent DNA replication
GO:0006310 DNA recombination
GO:0007059 chromosome segregation
GO:0007126 meiotic nuclear division
GO:0007127 meiosis I
GO:0007131 reciprocal meiotic recombination
GO:0031297 replication fork processing
GO:0035825 reciprocal DNA recombination
GO:0036297 interstrand cross-link repair
GO:0045005 DNA-dependent DNA replication maintenance of fidelity
GO:0045132 meiotic chromosome segregation
GO:0051304 chromosome separation
GO:0051307 meiotic chromosome separation
GO:0051321 meiotic cell cycle
GO:0090305 nucleic acid phosphodiester bond hydrolysis
GO:0098813 nuclear chromosome segregation
GO:1903046 meiotic cell cycle process
Molecular Function GO:0003682 chromatin binding
GO:0004386 helicase activity
GO:0004518 nuclease activity
Cellular Component GO:0043240 Fanconi anaemia nuclear complex
GO:0071821 FANCM-MHF complex
> KEGG and Reactome Pathway
 
KEGG hsa03460 Fanconi anemia pathway
Reactome R-HSA-73894: DNA Repair
R-HSA-6783310: Fanconi Anemia Pathway
Summary
SymbolFANCM
NameFanconi anemia, complementation group M
Aliases FAAP250; KIAA1596; ATP-dependent RNA helicase FANCM; fanconi anemia-associated polypeptide of 250 kDa; prote ......
Chromosomal Location14q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FANCM and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolFANCM
NameFanconi anemia, complementation group M
Aliases FAAP250; KIAA1596; ATP-dependent RNA helicase FANCM; fanconi anemia-associated polypeptide of 250 kDa; prote ......
Chromosomal Location14q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FANCM in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFANCM
NameFanconi anemia, complementation group M
Aliases FAAP250; KIAA1596; ATP-dependent RNA helicase FANCM; fanconi anemia-associated polypeptide of 250 kDa; prote ......
Chromosomal Location14q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FANCM in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0050.98
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2260.618
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1730.635
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2210.492
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0150.993
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.4840.811
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0470.854
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1050.921
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0230.983
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0790.918
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.6030.537
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.10.118
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FANCM in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.15.91.21
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414257.117.90.405
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277318.52.715.80.0147
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275918.53.415.10.0291
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFANCM
NameFanconi anemia, complementation group M
Aliases FAAP250; KIAA1596; ATP-dependent RNA helicase FANCM; fanconi anemia-associated polypeptide of 250 kDa; prote ......
Chromosomal Location14q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FANCM. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFANCM
NameFanconi anemia, complementation group M
Aliases FAAP250; KIAA1596; ATP-dependent RNA helicase FANCM; fanconi anemia-associated polypeptide of 250 kDa; prote ......
Chromosomal Location14q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FANCM. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FANCM.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFANCM
NameFanconi anemia, complementation group M
Aliases FAAP250; KIAA1596; ATP-dependent RNA helicase FANCM; fanconi anemia-associated polypeptide of 250 kDa; prote ......
Chromosomal Location14q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FANCM. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFANCM
NameFanconi anemia, complementation group M
Aliases FAAP250; KIAA1596; ATP-dependent RNA helicase FANCM; fanconi anemia-associated polypeptide of 250 kDa; prote ......
Chromosomal Location14q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FANCM expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFANCM
NameFanconi anemia, complementation group M
Aliases FAAP250; KIAA1596; ATP-dependent RNA helicase FANCM; fanconi anemia-associated polypeptide of 250 kDa; prote ......
Chromosomal Location14q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FANCM and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFANCM
NameFanconi anemia, complementation group M
Aliases FAAP250; KIAA1596; ATP-dependent RNA helicase FANCM; fanconi anemia-associated polypeptide of 250 kDa; prote ......
Chromosomal Location14q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FANCM collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.